香港航天科技(01725.HK)附屬發射衛星並進入預定軌道
香港航天科技(01725.HK)公佈,間接全資附屬公深圳港航科已於昨日(14日)於太原衛星發射中心用長徵二號丁運載火箭,成功發射一顆「金紫荊衛星二號」衛星,併成功進入預定軌道。該「金紫荊衛星二號」衛星與今年4月發射的兩顆「金紫荊衛星一號(01星及02星)」衛星一起構成「金紫荊星座」項目的第一編隊。
公司預計,今年年底前「金紫荊星座」項目第一編隊衛星的後續衛星將陸續發射,並預計可於2022年底前實現「金紫荊-齊魯」農業衛星星座的陸續發射。
「金紫荊星座」項目致力於以粵港澳大灣區爲重點對象打造智慧城市,通過在城市區域內融合信息化、 精細化管理和人工智能,實現可持續發展和創新。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.